Navigation Links
Enrollment Complete in Pivotal Phase 3 Trial of Medidur(TM) FA for Diabetic Macular Edema
Date:10/8/2007

ATLANTA, Oct. 8 /PRNewswire/ -- Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company, and pSivida Limited (Nasdaq: PSDV; ASX: PSD; Xetra: PSI), announced today that enrollment is complete for the FAME(TM) (Fluocinolone Acetonide in Diabetic Macular Edema) Study of Medidur(TM) FA for the treatment of Diabetic Macular Edema. FAME is a double masked, randomized, multi-center study that is following over 900 patients in the U.S., Canada, Europe and India for 36 months with safety and efficacy assessed at two years. Alimera Sciences and pSivida are jointly developing Medidur FA under a collaborative research and development agreement.

"Alimera Sciences is very excited to have completed enrollment in the FAME Study as this brings us closer to taking Medidur FA, the next generation of retinal drug delivery, to market and to our ultimate goal of delivering treatments that enrich patients' quality of life," said Alimera CEO Dan Myers.

Medidur, a tiny, injectable insert, is being studied as a way to deliver fluocinolone acetonide, a corticosteroid, to the retina for up to three years as a treatment for diabetic macular edema (DME). Using a proprietary 25 gauge injector system, an eye care professional injects the Medidur insert into the vitreous through a minimally invasive procedure in an outpatient setting.

"This marks an important milestone for the company in our profit sharing collaboration with Alimera. We are very pleased at the continued development of Medidur FA, based on our technologies that have already been approved for two back of the eye diseases. We are optimistic that Medidur FA will offer a solution to the large market we see for this product," said pSivida Limited Managing Director, Dr Paul Ashton.

Diabetic retinopathy (DR), a complication of diabetes mellitus, is the leading cause of blindness in the working-age population of developed countries. At any time during progression of diabetic retinopathy, pati
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
5. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
6. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
7. Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials
8. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
9. LANI completes Phase I in Japan and to commence Phase I in UK
10. GTx Announces Ostarine Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014   GS1 US ... implement GS1 Standards to support the 2013 Drug ... safety and security in the pharmaceutical supply chain. ... to U.S. Pharmaceutical Supply Chain Business Processes to ... was developed in collaboration with GS1 Healthcare ...
(Date:9/17/2014)... -- Sutro Biopharma, a biopharmaceutical company developing antibody drug ... Merck KGaA, Darmstadt, Germany , which ... States and Canada , ... antibody drug conjugates (ADCs). ADCs are composed of an ... thought to specifically target and deliver the cytotoxic drug ...
(Date:9/17/2014)... ARMONK, N.Y. , Sept. 17 2014 ... Caris Life Sciences is using IBM technical computing ... profiling services for cancer patients. These services deliver ... therapeutic plans for each patient,s unique cancer, which ... costs to the healthcare system in general. ...
Breaking Medicine Technology:New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 2Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 4
... MALVERN, Pa., May 17, 2012  Egalet Ltd., a privately ... and abuse-deterrent medications, announced today Bob Radie, president and ... Life Sciences Europe conference on May 23 organized ... the company,s patented technology and pipeline of abuse-deterrent opioids ...
... LOUIS, May 17, 2012 , "9 Trends" ... , Helping Members Make Healthier Decisions , ... , Developing New Ways to Comprehensively Manage Specialty Care ... Poor health choices add billions in cost to ...
Cached Medicine Technology:Egalet to Present at Life Sciences Europe Conference 2Poor Health Decisions Cost Billions; New Report Identifies Unhealthy Behavior as Top Concern of Benefit Providers 2Poor Health Decisions Cost Billions; New Report Identifies Unhealthy Behavior as Top Concern of Benefit Providers 3Poor Health Decisions Cost Billions; New Report Identifies Unhealthy Behavior as Top Concern of Benefit Providers 4Poor Health Decisions Cost Billions; New Report Identifies Unhealthy Behavior as Top Concern of Benefit Providers 5
(Date:9/17/2014)... Dennis Thompson HealthDay ... -- Diabetics and dieters who turn to artificial sweeteners ... themselves any favors, a new Israeli study suggests. ... despite containing no calories, researchers found in human and ... appear to alter the bacteria residing in the intestines ...
(Date:9/17/2014)... more than 87,000 men, a global team of scientists ... common differences in the genetic code -- that increase ... believed to be the largest of its kind, has ... array of ethnic groups comprising men of European, African, ... from smaller studies, according to William B. Isaacs, Ph.D., ...
(Date:9/17/2014)... Mercy “topped out” the world’s first ... beam into place. Sister of Mercy Claudia Ward also ... and video of the event, including footage from an ... http://bit.ly/MercyVirtual .) , “The topping out means we are ... thousands of patients regardless of the hour or location,” ...
(Date:9/17/2014)... Fremont, California (PRWEB) September 17, 2014 ... remote access connectivity solutions, today announced that it ... Appliance in October 2014. This new offering will ... 365 and other Software-as-a-Service applications to enable secure ... With the rise of cloud computing, there has ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. ... companies have made good on their pledge to cut calories ... companies, acting together through the Healthy Weight Commitment Foundation, pledged ... and 2012 and 1.5 trillion by 2015. They,ve actually reduced ... met their pledge and exceeded their pledge," said lead researcher ...
Breaking Medicine News(10 mins):Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3Health News:Large study reveals new genetic variants that raise risk for prostate cancer 2Health News:Mercy Tops Out World's First Virtual Care Center 2Health News:Celestix Announces Availability of ADFS Bridge Appliance in October 2014 to Simplify the Configuration of Office 365 with Active Directory 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3
... Kiley Carlson of Sioux City, IA will travel ... 31, 2009 to meet with congressional leaders and gain ... research toward a cure for epilepsy.Carlson, 16, is one ... in Kids Speak Up! , a national program ...
... Findings of Pilot Study at East African Health Conference ... Danya International, Inc. (Danya), a communications, research, ... pilot study on the effectiveness of mobile video-enabled phones ... tuberculosis (TB) patients during the 3rd East African Health ...
... Milwaukee MD Saves Patients Money and Improves Health ... To save you money and save your ... may need to be part medical detective as ... http://www.newscom.com/cgi-bin/prnh/20090323/NY86411-a ) , (Photo: http://www.newscom.com/cgi-bin/prnh/20090323/NY86411-b ...
... HOUSTON - Just more than one year after it was ... of Texas M. D. Anderson Cancer Center has introduced a ... generations of women scientists to come. , Legends and ... D. Anderson Cancer Center presents the reflections of 26 current ...
... statutory health insurances in Germany have offered an endoscopic ... all insured persons from the age of 55. Germany ... for bowel cancer a part of its statutory early ... Professor Hermann Brenner at DKFZ have now published a ...
... Scientists at the University of Liverpool have demonstrated how ... be a source of Salmonella transmission to ... living creatures that can contaminate almost any food type, ... that Salmonella which can also cause ...
Cached Medicine News:Health News:Iowa Youth Shares Epilepsy Message on Capitol Hill 2Health News:Pilot Study Using Video Cell Phones for Mobile Direct Observation Treatment (MDOT) to Monitor Medication Compliance of TB Patients 2Health News:Pilot Study Using Video Cell Phones for Mobile Direct Observation Treatment (MDOT) to Monitor Medication Compliance of TB Patients 3Health News:Pilot Study Using Video Cell Phones for Mobile Direct Observation Treatment (MDOT) to Monitor Medication Compliance of TB Patients 4Health News:Saving Money While Protecting Your Health in Tough Economic Times 2Health News:Saving Money While Protecting Your Health in Tough Economic Times 3Health News:New book chronicles the journeys of women physicians and scientists to fighting cancer 2Health News:New book chronicles the journeys of women physicians and scientists to fighting cancer 3Health News:New book chronicles the journeys of women physicians and scientists to fighting cancer 4Health News:Germany: Colonoscopy prevents 15,000 cancer cases 2Health News:Study shows how Salmonella survives in environment 2
Two-channel, Berman design. Semirigid, nontoxic polyethylene. Individually packaged, 48 per case. Latex Free....
Black elastomer. Smooth finish. Non-Sterile....
Guedel-style enclosed center channel. Semirigid, nontoxic polyethylene with color-coded bite block. Individually packaged, 48 per case. Latex Free....
Includes one of each size airway. Plastic. Color coded for size. Single use. Non-Sterile....
Medicine Products: